Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19)

Respiratory Distress Syndrome Clinical Trial

Official title:
Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19)

Status Recruiting

Clinical Trial Summary

Recent advances have been made in prevention of the viral infection via vaccines but there is still need for effective treatment options for patients. Novel therapies need to be developed to further improve clinical outcomes. The biggest medical challenge in the response to COVID-19 is ARDS requiring hospitalization in an intensive care setting and ventilator dependence. Intravenously administered umbilical cord derived exosomes and stem cells have been reported in literature to alleviate pulmonary distress in such patients. The purpose of this study is to explore the safety and benefits of intravenous administration of WJPure and EVPure in the treatment of COVID-19 patients with moderate to severe ARDS. .

Clinical Trial Description

One of the hallmark features of the progression of COVID-19 is lung injury from the viral infection leading to potentially acute respiratory distress syndrome (ARDS) and respiratory failure requiring ventilator support. In patients who survive ARDS, regardless of the pathology, there is evidence that their long-term quality of life is adversely affected. The rationale for the dose and dosing regimen proposed in this study is based on the safe administration and benefits of this treatment regimen reported to us last year by physicians trying to treat moderate to severe COVID-19 patients. In those reports, the intravenous route of administration was used. It has been reported that dosing every 2 days amplified the benefit of the combination of exosomes and mesenchymal stem cells. It has been suggested based on clinical experience that the exosomes and MSCs are complementary to one another as well as enhancing the innate abilities of both. During the early days of the pandemic, intravenous infusion of a mixture of EV-Pure™ and WJ-Pure™ was reported to benefit hospitalized patients with moderate to severe COVID-19 related ARDS. This study is designed to systematically explore the risk and benefits of intravenous infusion of EV-Pure™ and WJ-Pure™ in the treatment of hospitalized COVID-19 patients with moderate to severe ARDS. This is a proof of concept, double-blind, placebo-controlled trial to evaluate the safety and efficacy of intravenous infusion of EV-Pure™ and WJ-Pure™, versus placebo, for use in the treatment of moderate to severe ARDS related to COVID-19. This is an add-on treatment study; subjects will be allowed to take standard of care treatments available. The study will have two arms (n=10 each): 1. Experimental/treatment arm: EV-Pure™ and WJ-Pure™ plus standard care 2. Placebo: Cryopreservation media plus standard care The study duration would be 5 days of treatment plus 12 weeks follow up. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05387278
Study type	Interventional
Source	Vitti Labs, LLC
Contact	Mukesh Kumar
Phone	2407504893
Email	mkumar@fdamap.com
Status	Recruiting
Phase	Phase 1
Start date	March 20, 2023
Completion date	December 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT06168149` - The Relationship of Fetal Lung Elastography Values With the Development of Respiratory Distress in Cases of Preterm Labor
Recruiting	`NCT03670732` - CPAP vs.Unsynchronized NIPPV at Equal Mean Airway Pressure	N/A
Recruiting	`NCT02901652` - NIPPV and nBiPAP Methods in Preterm Infants With Respiratory Distress Syndrome	N/A
Completed	`NCT02249143` - Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants	N/A
Suspended	`NCT01852916` - NHFOV Versus NCPAP to Prevent Exubation Failure	N/A
Completed	`NCT00208039` - Pilot Trial of Surfactant Booster Prophylaxis For Ventilated Preterm Neonates	N/A
Recruiting	`NCT03510169` - Use of Gentle Synchronized Negative Pressure in Helping Babies Breathe	N/A
Completed	`NCT00004494` - Phase I Study of Vasoactive Intestinal Peptide in Patients With Acute Respiratory Distress Syndrome and Sepsis	Phase 1
Completed	`NCT00006058` - Study of the Pathobiology of Bronchopulmonary Dysplasia in Newborns	N/A
Completed	`NCT00004805` - Study of the Effect of Four Methods of Cardiopulmonary Resuscitation Instruction on Psychosocial Response of Parents With Infants at Risk of Sudden Death	N/A
Completed	`NCT03292562` - A Comparison of Methods of Discontinuing Nasal CPAP in Premature Infants <30 Weeks Gestation	N/A
Completed	`NCT05948332` - Definition and Management of Right Ventricular Injury in Adult Patients Receiving Extracorporeal Membrane Oxygenation
Not yet recruiting	`NCT05508724` - Recruitment Manoeuvres in Critically Ill Patients
Completed	`NCT05038514` - The Effect of Music Therapy in COVID-19 Patients Given Prone Position	N/A
Active, not recruiting	`NCT04079829` - Postoperative Respiratory Abnormalities
Completed	`NCT05462509` - Feasibility of Use of the PATH bCPAP and Oxygen Blenders Device With Neonates in Uganda	N/A
Active, not recruiting	`NCT03808402` - The Effect of Surfactant Dose on Outcomes in Preterm Infants With RDS
Completed	`NCT01812681` - Cord Blood 25(oh)-Vitamin D Level in Preterm Infants and Associated Morbidities	N/A
Completed	`NCT01517958` - Lung Ultrasound to Diagnose Transient Tachypnea of the Newborn (TTN) Versus Respiratory Distress Syndrome (RDS) in Neonates	N/A
Not yet recruiting	`NCT01440868` - Sustained Lung Inflation in the Delivery Room in Preterm Infants at High Risk of Respiratory Distress Syndrome	N/A